Exact Sciences traded at $103.43 this Friday February 20th, increasing $0.14 or 0.14 percent since the previous trading session. Looking back, over the last four weeks, Exact Sciences gained 0.93 percent. Over the last 12 months, its price rose by 109.97 percent. Looking ahead, we forecast Exact Sciences to be priced at 100.22 by the end of this quarter and at 91.19 in one year, according to Trading Economics global macro models projections and analysts expectations.
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.